mutLBSgeneDB |
Gene summary for DUS2 |
![]() |
Basic gene Info. | Gene symbol | DUS2 |
Gene name | dihydrouridine synthase 2 | |
Synonyms | DUS2L|SMM1|URLC8 | |
Cytomap | UCSC genome browser: 16q22.1 | |
Type of gene | protein-coding | |
RefGenes | NM_001271762.1, NM_001271763.1,NM_017803.4, | |
Description | SMM1 homologdihydrouridine synthase 2-like, SMM1 homologtRNA-dihydrouridine(20) synthase [NAD(P)+]-likeup-regulated in lung cancer protein 8 | |
Modification date | 20141207 | |
dbXrefs | MIM : 609707 | |
HGNC : HGNC | ||
Ensembl : ENSG00000167264 | ||
HPRD : 08624 | ||
Vega : OTTHUMG00000137538 | ||
Protein | UniProt: Q9NX74 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_DUS2 | |
BioGPS: 54920 | ||
Pathway | NCI Pathway Interaction Database: DUS2 | |
KEGG: DUS2 | ||
REACTOME: DUS2 | ||
Pathway Commons: DUS2 | ||
Context | iHOP: DUS2 | |
ligand binding site mutation search in PubMed: DUS2 | ||
UCL Cancer Institute: DUS2 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
![]() |
GO ID | GO Term | PubMed ID | GO:0006469 | negative regulation of protein kinase activity | 18096616 | GO:0060548 | negative regulation of cell death | 18096616 |
Top |
Ligand binding site mutations for DUS2 |
![]() |
LBS | AAchange of nsSNV | Cancer type | # samples | V20 | R21L | LUAD | 1 | G216 | G216V | LUAD | 1 | E43 | L44P | SKCM | 1 | H183 | V182I | THCA | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for DUS2 |
![]() Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
![]() ![]() |
![]() |
![]() Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | E43 | L44P | -1.1787514 | H183 | V182I | -1.1267951 | V20 | R21L | -0.72012311 | G216 | G216V | -0.59259412 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
![]() |
Top |
Differential gene expression and gene-gene network for DUS2 |
![]() |
![]() |
Top |
Top |
Phenotype information for DUS2 |
![]() |
Disease ID | Disease name | # PubMed | Association type |
![]() |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for DUS2 |
![]() Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
![]() |
![]() |
Drug status | DrugBank ID | Name | Type | Drug structure |
![]() |
![]() |
![]() |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | FNR | REDUCED FMN | 4xp7 | A | V20 E43 H183 G216 | FMN | FLAVIN MONONUCLEOTIDE | 4wfs | A | V20 E43 H183 G216 |
Top |
Conservation information for LBS of DUS2 |
![]() |
LBS | AA sequence | # species | Species |
![]() |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |